WO2024095137 - PHARMACEUTICAL COMPOSITION OF EMPAGLIFLOZIN AND PROCESS THEREOF

National phase entry is expected:
Publication Number WO/2024/095137
Publication Date 10.05.2024
International Application No. PCT/IB2023/060936
International Filing Date 31.10.2023
Title [English] PHARMACEUTICAL COMPOSITION OF EMPAGLIFLOZIN AND PROCESS THEREOF [French] COMPOSITION PHARMACEUTIQUE D'EMPAGLIFLOZINE ET PROCÉDÉ ASSOCIÉ
Applicants ** MOREPEN LABORATORIES LIMITED Morepen Village, Malkumajra, Distt. Solan, Himachal Pradesh (H.P) Baddi 173205, IN
Inventors ** CHATURVEDI, Kiran Morepen Laboratories Limited Morepen Village, Malkumajra, Distt. Solan, Himachal Pradesh Baddi 173205, IN SAXENA, Arjit Morepen Laboratories Limited Morepen Village, Malkumajra, Distt. Solan, Himachal Pradesh Baddi 173205, IN SURI, Sanjay Morepen Laboratories Limited Morepen Village, Malkumajra, Distt. Solan, Himachal Pradesh Baddi 173205, IN
Priority Data 202211063288  05.11.2022  IN
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 925
EPO Filing, Examination 6521
Japan Filing 571
South Korea Filing 578
USA Filing, Examination 2635
MasterCard Visa
Total: 11230
Abstract [English] The present invention relates to a stable pharmaceutical composition of empagliflozin or its pharmaceutically acceptable salts, solvates thereof along with one or more pharmaceutically acceptable excipients. More specifically, the present invention relates to a process of preparing a stable pharmaceutical composition of empagliflozin. [French] La présente invention concerne une composition pharmaceutique stable d'empagliflozine ou de ses sels pharmaceutiquement acceptables, des solvates de celle-ci conjointement avec un ou plusieurs excipients pharmaceutiquement acceptables. Plus spécifiquement, la présente invention concerne un procédé de préparation d'une composition pharmaceutique stable d'empagliflozine.